Nuevos biomateriales: estudio in vivo del carburo de silicio como material osteointegrador / New biomaterials: in vivo study of silicon carbide as boneintegration material

Objetivo: Evaluar, mediante ensayos in vivo, la biocompatibilidad y el grado de penetración ósea en la microestructura porosa del carburo de silicio (SiC). Material y métodos: se implantaron en cóndilos femorales de conejos cilindros de SiC obtenidos a partir de maderas de pino y sapeli. Como material de referencia fueron utilizados cilindros de titanio. El sacrificio de los animales se realizó a las 12 semanas de implantación y se procedió al examen histológico de las muestras. Resultados: Comprobamos un crecimiento de trabéculas óseas, tanto en la superficie del implante como a través de su estructura porosa, sin apreciarse signos de inflamación ni aparición de tejido fibroso alrededor de la muestra. Estos resultados son confirmados mediante microscopía electrónica de barrido (SEM) y análisis de rayos X por dispersión de energías. Conclusión: El carburo de silicio biomórfico es una cerámica con excelentes propiedades mecánicas y porosidad interconectada que le confiere un especial atractivo de cara a sus aplicaciones biomédicas en implantes ortopédicos (AU)

Objective: To evaluate, using in vivo tests, the biocompatibility and the degree of bone penetration into the porous microstructure of silicon carbide (SiC). Material and methods: For this purpose cylindres of SiC obatained from wood of pine and sapeli were implanted in femoral condyles of rabbits. As reference material we used titanium cylinders. The slaughter of animals was performed at 12 weeks of implantation and proceeded to the histological examination of the samples. Results: We see a growth of bone trabeculae, both on the surface of the implant and through its porous structure, without signs of inflammation or appearance of fibrous tissue around the samples. These results are confirmed by scanning electron microscopy scanning (SEM) and X-ray analysis by dispersion of energies (EDS). Conclusion: Biomorphic silicon carbide (SiC) is a ceramic with excellent mechanical properties and interconnected porosity which gives a special attraction for their biomedical applications in orthopaedic implants (AU)

Effects of medetomidine on Doppler variables of major abdominal arteries in normal dogs.

The purpose of this study was to evaluate the effects of medetomidine administration on the Doppler variables of abdominal arteries. The study population consisted of 20 healthy dogs. The haemodynamic effects of the medetomidine were defined using Doppler variables of the abdominal aorta, renal arteries, cranial mesenteric artery and celiac artery. The dogs were monitored continuously and different measurements were performed before medetomidine injection, at 10, 40 and 80 minutes after medetomidine medication and after atipamezole administration. Changes in the characteristic Doppler spectra of different vessels were more marked in the abdominal aorta, in which a greater reverse flow was found. There was a significant decrease in peak systolic velocity (PSV), end diastolic velocity (EDV), and mean velocity (MV) at ten minutes in every vessel studied and this effect persisted until atipamezole administration. Pulsatility index (PI) increased significantly in the abdominal aorta at ten minutes and persisted during the study until atipamezole administration. Resistive index (RI) did not vary significantly in any vessel. A significant decrease was found in flow volume of the abdominal aorta, the cranial mesenteric artery and the celiac artery at ten minutes, persisting until atipamezole administration. We conclude that medetomidine can be a good sedative in aiding sonographic evaluation of RI in all the abdominal vessels studied. On the other hand, the changes in other Doppler variables suggest that medetomidine administration causes significant hemodynamic differences between sedated and non-sedated dogs.

Meningoencephalitis associated with Staphylococcus warneri in a dog.

A case of meningoencephalitis in a dog caused by Staphylococcus warneri is reported here. The history and clinical signs were suggestive of possible central nervous system infection. Analysis of cerebrospinal fluid documented a neutrophilic pleocytosis (890 cells/mul) and the presence of occasional intracellular cocci. Staphylococcus warneri was isolated from the microbiological culture of the cerebrospinal fluid. Treatment consisted of intravenous antibiotics, supportive care and anticonvulsants for the generalised seizures that developed after admission. Histological assessment confirmed the location and extension of bacterial meningoencephalitis. Thrombotic meningoencephalitis associated with Staphylococcus warneri infection has not, to the authors' knowledge, been previously reported in dogs.

Suspected lasalocid poisoning in three dogs.

The ionophore lasalocid has been used as a feed additive for broilers chickens and for improving feed efficiency in ruminants. Although dogs appear to be more sensitive to lasalocid intoxication than other species, there is only 1 report in the veterinary literature about lasalocid poisoning in dogs. We describe the clinical signs, treatment and resolution of 3 hunting dogs that developed acute neurological signs consistent with lasalocid poisoning after the consumption of several broilers that had died on a nearby farm.

Development of polyuria in Tsukuba hypertensive mice carrying human renin and angiotensinogen genes.

1. Tsukuba hypertensive mice (THM) carry both human renin and angiotensinogen genes, and develop hypertension. The animal has high levels of renin activity and angiotensin II concentration in the plasma. 2. Urinary excretion in THM was greater than in the control animal, non-transgenic C57BL/6j. THM showed a greater amount of daily water intake. The osmolality of 24 h urine was lower than that of the control animal. 3. When water was deprived for 12 h and then loaded with 0.25 mL/10 g bodyweight, the osmolality of urine at the first 0-3 h period was the same in THM and control, but significantly lower in THM at the following 3-6 h period, indicating that the urine concentrating activity is insufficient in THM compared with the control animal. 4. Urinary excretion of vasopressin was significantly higher in THM. Plasma aldosterone concentration and urinary excretion of aldosterone were also higher in THM. Plasma potassium level was significantly low. 5. The mechanism underlying the pathophysiology of polyuria is not totally explained; however, hypokalaemia, which was probably the result of hyperaldosteronism, may be at least partially involved, since hypokalaemia is considered to be a factor hampering the action of vasopressin for concentration of urine at the site of the collecting duct of the kidney.

Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788.

We describe the characteristics of a potent and selective endothelin (ET) B-receptor antagonist, BQ-788 [N-cis-2,6-dimethylpiperidinocarbonyl-L-gamma-methylleucyl-D -1- methoxycarbonyltryptophanyl-D-norleucine]. In vitro, this compound potently and competitively inhibits 125I-labeled endothelin 1 (ET-1) binding to ETB receptors on human Girardi heart cells (IC50, 1.2 nM) but only poorly inhibits the binding to ETA receptors on human neuroblastoma cell line SK-N-MC cells (IC50, 1300 nM). In isolated rabbit pulmonary arteries, BQ-788 shows no agonist activity up to 10 microM and competitively antagonizes the vasoconstriction induced by an ETB-selective agonist, BQ-3020 (pA2, 8.4). In rat, an ETA-selective antagonist, BQ-123 (1 mg/kg, i.v.), does not affect transient depressor response to ET-1 (0.3 nmol/kg, i.v.) but potently inhibits following sustained pressor response; vice versa, BQ-788 (1 mg/kg, i.v.) abolishes the depressor response, resulting in a rapid onset of apparently enhanced pressor response. Thus, being a potent and selective ETB receptor antagonist, BQ-788 may be considered as a powerful tool for investigating the role of ET in physiological and pathological processes.

Protective effect of a selective endothelin receptor antagonist, BQ-123, in ischemic acute renal failure in rats.

To elucidate the pathophysiological role of endogenous endothelin (ET), we examined the effects of the newly synthesized ETA receptor-selective antagonist, BQ-123, on ischemic acute renal failure induced by bilateral clamping of renal artery and vein followed by reperfusion in rats. BQ-123, when given by i.v. infusion of 0.5 mg/kg per min for 2.5 h during the pre- and post-ischemic period, was found to prevent the decrease in creatinine clearance and increases in blood urea nitrogen, plasma creatinine and the fractional excretion of sodium. Morphological observation also showed an effect of BQ-123, i.e. prevention of proximal tubular (S3 segment) necrosis. At 2 h after the start of reperfusion, the ET-1 content in the kidney increased to its maximal level. At this time, the Ca2+ content in the mitochondrial fraction of the renal cortex increased, with a concomitant increase in blood urea nitrogen. However, these increases were limited by treatment with BQ-123. Thus, BQ-123 was effective to both prevent mitochondrial Ca2+ accumulation in the early phase of ischemic acute renal failure and protect proximal tubular cells from post-ischemic degeneration. We conclude that ET may be at least partially involved in the pathogenesis of tubular cell injury in this acute renal failure model.

A novel nonpeptidic, orally active renin inhibitor.

BW-175 is a newly synthesized renin inhibitor which is a nonpeptidic, norleucine analog. Its IC50 values for renin activity in human, squirrel monkey, marmoset, dog, hog, rabbit and rat plasma were 3.3, 6.6, 2.4, 42, 110, 86 and 3500 nM, respectively, and 26 microM for cathepsin D. Pepsin and angiotensin converting enzyme were hardly inhibited at 10(-4) M. BW-175 showed an oral bioavailability of 2.8% at 10 mg/kg and 9.7% at 30 mg/kg in rats. In normotensive, furosemide-treated high-renin marmosets, BW-175 (30 mg/kg p.o.) caused an intensive reduction in plasma renin activity and plasma angiotensin I formation, associated with a reduction in systolic blood pressure of 10-20 mm Hg for 2 hours.

Availability of tumor-antigen 4 as a marker of squamous cell carcinoma of the lung and other organs.

The serum level of tumor-antigen 4 (TA-4) was measured in 401 patients with squamous cell carcinoma (SCC) of various organs (76 lung, 82 esophagus, and 234 head and neck). The mean serum level of TA-4 in patients with lung SCC was 3.6 times higher than that in healthy controls and even higher in the advanced stages of disease (III, IV). In patients with benign diseases or other types of lung cancer, however, the TA-4 serum level was not different from the controls regardless of the clinical stage. During radiation therapy, the TA-4 levels in patients with lung SCC decreased with reduction in tumor size. It increased again markedly during recurrence. Similarly, patients with SCC of the esophagus and head and neck also showed elevated TA-4 levels but only at advanced stages and in recurrence. It was concluded that TA-4 is highly related to SCC not only of the uterine cervix but also of other organs and that serum level determinations are useful for monitoring therapeutic effects and recurrence of these diseases, despite some limitations.

[An immunoradiometric assay of serum SCC antigen using a monoclonal antibody--a comparison with the conventional double antibody method].

The serum level of the squamous cell carcinoma-related antigen (SCC-Ag) has been measured by a new immunoradiometric assay (IRMA) method that has been recently developed by using a monoclonal antibody, and compared with the results obtained by the conventional double-antibody method using a polyclonal antibody. Both methods gave essentially the same results, that the serum SCC-Ag level was high in patients with squamous cell carcinoma of various organs when compared with other types of lung cancer or benign diseases. However, the percentages of the serum SCC-Ag level over the normal range were found to be higher by the new IRMA method than by the conventional method. This may be due to the improvement in sensitivity and accuracy of this newer method of assay, which also results in a considerable decrease in the normal range estimated in healthy subjects. Therefore, it has been concluded that this new method is more suitable than the conventional method for an early diagnosis of squamous cell carcinoma in all organs.